 Connection
Patrick Johnston to Cytarabine
This is a "connection" page, showing publications Patrick Johnston has written about Cytarabine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.066 |
|
|
|
-
Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct; 92(10):1004-1010.
Score: 0.032
-
Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol. 2008 Oct; 143(2):268-73.
Score: 0.017
-
Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma. 2007 Jul; 48(7):1332-7.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|